PI3K/mTOR 抑制剂诱导癌细胞中的上下文依赖的亡和甲化
Xiaoyuan Hua1, Panpan Chen1, Wanjing Zeng1
1Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.
Pharmaceuticals (Basel, Switzerland)
|December 31, 2025
概括
双PI3K/mTOR抑制剂YYN-37通过诱导细胞亡或VPS34介导的甲化,即非细胞亡的细胞死亡,有效地向癌细胞. 这为抗亡的癌症提供了一种新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 针对PI3K/mTOR途径对于癌症治疗至关重要.
- 耐亡性限制了当前癌症治疗的有效性.
- 除了细胞亡之外,研究新的细胞死亡机制是必不可少的.
研究的目的:
- 为了研究双PI3K/mTOR抑制剂YYN-37.
- 探索YYN-37诱导情境依赖性细胞死亡的能力,包括化.
- 评估VPS34在YYN-37诱导的细胞死亡中的作用.
主要方法:
- 使用了HCT-116和SJSA-1癌细胞系.
- 进行了细胞活力测定,西斑和光痕迹仪.
- 采用了特定途径的抑制剂,VPS34敲击,蛋白质基因分析和体内异种移植模型.
主要成果:
- 在HCT-116细胞中诱导YYN-37的亡,在SJSA-1细胞中诱导VPS34依赖的甲化 (细胞质真空化).
- YYN-37直接抑制了VPS34 (IC50 = 2.73 nM). 这是一个非常明显的结果.
- 在体内,YYN-37显示出显著的抗瘤功效 (72.71%的增长抑制).
结论:
- YYN-37通过亡或化表现出强大的,取决于背景的抗瘤作用.
- 甲症诱导是一种可行的治疗策略,用于对亡耐药的癌症.
- VPS34抑制是癌症治疗的一个有希望的机制.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
The Intrinsic Apoptotic Pathway
8.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
Abnormal Proliferation
5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Interactions Between Signaling Pathways
7.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K


